DB
CSCI

Danske Bank’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Danske Bank’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$7 – 1679
2024
Q3 		$7 Buy
+2
New +$10 ﹤0.01% 1543

Other funds holding CSCI

National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Danske Bank's CSCI Position: Q4 2024 in Review

Danske Bank sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q4 2024, closing a stake of 2 shares — an estimated $7 sold.

Danske Bank first reported a position in CSCI in Q3 2024 and held it in 1 quarter. The position peaked at $7 in Q3 2024. 15 funds tracked by Wall St. Rank hold CSCI as of Q4 2024.

  • Danske Bank reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Danske Bank sold 2 COSCIENS Biopharma Inc. Common Stock shares in Q4 2024, an estimated $7.
  • Danske Bank first reported a position in COSCIENS Biopharma Inc. Common Stock in Q3 2024 and held it in 1 quarter.
  • Danske Bank's COSCIENS Biopharma Inc. Common Stock position peaked at $7 in Q3 2024.
  • 15 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.